Guideline-oriented ambulatory lipid-lowering therapy of patients at high risk for cardiovascular events by cardiologists in clinical practice: the 2L cardio registry

Abstract

Background

Lipid-lowering treatment has been proven to decrease the rate of cardiovascular events in high-risk patients with manifest coronary artery disease (CAD) or CAD equivalent risk profile. Current treatment guidelines recommend low-density lipoprotein-cholesterol (LDL-C) less than 100 mg/dl (optional < 70 mg/dl) as the target level for this high-risk population. Little is known about the ambulatory treatment of high-risk patients in clinical practice and the achievement of guideline recommended target values.

Methods and results

In the ‘2L cardio’ registry in Germany, 295 cardiologists enrolled 6711 consecutive patients with known CAD, and/or diabetes mellitus, peripheral arterial disease (summarized as ‘coronary risk equivalent’, CE), on chronic statin treatment. They recorded actual LDL-C values at entry, probable changes in therapy, and the expected LDL-C values using a lipid calculator based on an earlier observational study in a similar setting. The three groups comprised 2618 patients with CAD plus CE (39.0%; median LDL-C 112 mg/dl), 3436 patients with CAD only (51.2%; median LDL-C 108 mg/dl), and 657 with CE only (9.8%; median LDL-C 124 mg/dl). They had LDL-C levels less than 100 mg/dl in 36.2% [95% confidence intervals (CI): 34.3–38.1], 39.7% (CI: 38.0–41.4), and 27.2% (CI: 23.7–30.7), respectively. Statin doses at entry were usually in the lower to intermediate range (e.g. simvastatin median 25 mg/day). Cardiologists switched to another statin in 10.1% (9.4–10.8), increased the dose of statins (if same drug) in 22.2% (CI: 21.1–23.2) and/or added a cholesterol absorption inhibitor in 23.7% (CI: 22.7–24.7) of the patients. The cardiologists’ intervention improved expected LDL-C levels in the total cohort by a mean of 9.0 mg/dl, but the 100 mg/dl LDL-C target was only reached in 51.3% (CI: 50.0–52.5) of the total cohort. CE patients appeared undertreated in terms of antiplatelet drugs.

Discussion

Through infrequent increases in statin doses and mainly through add-on of a cholesterol absorption inhibitor, cardiologists improved target level attainment. Compared with earlier studies in the outpatient setting, the treatment to target for LDL-C of high-risk CAD patients has improved, but is not satisfactory.

Keywords

coronary artery disease drug treatment guideline adherence high-density lipoproteins hypercholesterolemia risk stratification statins

Get full access to this article

View all access options for this article.

References

1 Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002; 106:3143–3421.

O'Keefe

Jr Cordain

Harris

Moe

Vogel

Optimal low-density lipoprotein is 50–70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol 2004; 43:2142–2146.

3 Grundy

Cleeman

Merz

Brewer

Jr Clark

Hunninghake

. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110:227–239.

4 NCEP. ATP III Guidelines At-A-Glance Quick Desk Reference. Available at: http://www.nhlbi.nih.gov/guidelines/cholesterol/atglance.pdf. [Accessed 18 March 2009].

5 De Backer

Ambrosioni

Borch-Johnsen

Brotons

Cifkova

Dallongeville

. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J 2003; 24:1601–1610.

6 Ryden

Standl

Bartnik

Van den Berghe

Betteridge

de Boer

. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary: the Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28:88–136.

7 Yan

Yan

Tan

Hackam

Leblanc

Kertland

. Contemporary management of dyslipidemia in high-risk patients: targets still not met. Am J Med 2006; 119:676–683.

Smith

Abdullah

Amirfarzan

Schwamm

LH.

Serum lipid profile on admission for ischemic stroke: failure to meet National Cholesterol Education Program Adult Treatment Panel (NCEP-ATPIII) guidelines. Neurology 2007; 68:660–665.

Alsheikh-Ali

Lin

Abourjaily

Ahearn

Kuvin

Karas

RH.

Extent to which accepted serum lipid goals are achieved in a contemporary general medical population with coronary heart disease risk equivalents. Am J Cardiol 2006; 98:1231–1233.

10.

Keevil

Cullen

Gangnon

McBride

Stein

JH.

Implications of cardiac risk and low-density lipoprotein cholesterol distributions in the United States for the diagnosis and treatment of dyslipidemia: data from National Health and Nutrition Examination Survey 1999–2002. Circulation 2007; 115:1363–1370.

11.

Kotseva

Wood

Backer

Bacquer

Pyorala

Keil

EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009 [Mar 12, Epub ahead of print].

12.

Friedmann

Brett

Mayo-Smith

MF.

Differences in generalists' and cardiologists' perceptions of cardiovascular risk and the outcomes of preventive therapy in cardiovascular disease. Ann Intern Med 1996; 124:414–421.

13.

13 Mosca

Linfante

Benjamin

Berra

Hayes

Walsh

. National study of physician awareness and adherence to cardiovascular disease prevention guidelines. Circulation 2005; 111:499–510.

14.

Pearson

Denke

McBride

Battisti

Brady

Palmisano

A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin Proc 2005; 80:587–595.

15.

Whiteley

Padmanabhan

Hole

Isles

Should diabetes be considered a coronary heart disease risk equivalent? Results from 25 years of follow-up in the Renfrew and Paisley survey. Diabetes Care 2005; 28:1588–1593.

16.

Juutilainen

Lehto

Ronnemaa

Pyorala

Laakso

Type 2 diabetes as a coronary heart disease equivalent: an 18-year prospective population-based study in Finnish subjects. Diabetes Care 2005; 28:2901–2907.

17.

Heald

Fowkes

Murray

Price

JF.

Risk of mortality and cardiovascular disease associated with the ankle-brachial index: systematic review. Atherosclerosis 2006; 189:61–69.

18.

18 Hirsch

Criqui

Treat-Jacobson

Regensteiner

Creager

Olin

. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001; 286:1317–1324.

19.

19 Hirsch

Haskal

Hertzer

Bakal

Creager

Halperin

. ACC/AHA guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic). Circulation 2006; 113:463–654.

20.

20 Pittrow

Trampisch

Paar

Mahn

Haberl

Darius

. Substantial differences in medical care: undertreatment of patients with PAD compared to patients with CHD [original in German]. Cardiovasc 2007; 5:36–39.

21.

21 American Diabetes Association. Peripheral arterial disease in people with diabetes. Diabetes Care 2003; 26:3333–3341.

22.

22 American Diabetes Association. Standards of medical care in diabetes– 2007. Diabetes Care 2007; 30:S4–S41.

23.

23 Belch

MacCuish

Campbell

Cobbe

Taylor

Prescott

. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008; 337:a1840.

24.

24 Pittrow

Kirch

Bramlage

Lehnert

Hofler

Unger

. Patterns of antihypertensive drug utilization in primary care. Eur J Clin Pharmacol 2004; 60:135–142.

25.

Shah

Hux

Austin

PC.

Diabetes is not treated as a coronary artery disease risk equivalent. Diabetes Care 2007; 30:381–383.

26.

Shah

Hux

Laupacis

Zinman

van Walraven

Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians? Diabetes Care 2005; 28:600–606.

27.

27 Grant

Cagliero

Dubey

Gildesgame

Chueh

Barry

. Clinical inertia in the management of type 2 diabetes metabolic risk factors. Diabet Med 2004; 21:150–155.

28.

Law

Wald

Rudnicka

AR.

Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ 2003; 326:1423–1430.

29.

Hildemann

Barho

Karmann

Darius

Bestehorn

Dual cholesterol inhibition with ezetimibe/simvastatin in pre-treated hypercholesterolaemic patients with coronary heart disease or diabetes mellitus: prospective observational cohort studies in clinical practice. Curr Med Res Opin 2007; 23:713–719.

30.

Pearson

Laurora

Chu

Kafonek

The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000; 160:459–467.

31.

McBride

Schrott

Plane

Underbakke

Brown

RL.

Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease. Arch Intern Med 1998; 158:1238–1244.

32.

Ruof

Klein

Marz

Wollschlager

Neiss

Wehling

Lipid-lowering medication for secondary prevention of coronary heart disease in a German outpatient population: the gap between treatment guidelines and real life treatment patterns. Prev Med 2002; 35:48–53.

33.

Krone

Böhm

Wöhrmann

Bestehorn

Erhebung und Verbesserung der Behandlungssituation von Patienten mit Diabetes mellitus. Das DUTY-Register. Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz 2004; 47:540–546.

34.

Assmann

Benecke

Neiss

Cullen

Schulte

Bestehorn

Gap between guidelines and practice: attainment of treatment targets in patients with primary hypercholesterolemia starting statin therapy. Results of the 4E-Registry (Efficacy Calculation and Measurement of Cardiovascular and Cerebrovascular Events Including Physicians' Experience and Evaluation). Eur J Cardiovasc Prev Rehabil 2006; 13:776–783.

35.

35 LaRosa

Grundy

Waters

Shear

Barter

Fruchart

. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352:1425–1435.

36.

Ahmed

Cannon

Murphy

Braunwald

Acute coronary syndromes and diabetes: is intensive lipid lowering beneficial? Results of the PROVE IT-TIMI 22 trial. Eur Heart J 2006; 27:2323–2329.

37.

37 Barter

Gotto

LaRosa

Maroni

Szarek

Grundy

. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007; 357:1301–1310.

38.

38 Deedwania

Barter

Carmena

Fruchart

Grundy

Haffner

. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet 2006; 368:919–928.

39.

39 Shepherd

Barter

Carmena

Deedwania

Fruchart

Haffner

. Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study. Diabetes Care 2006; 29:1220–1226.